King's College London

Research portal

The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study

Research output: Contribution to journalArticlepeer-review

Standard

The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study. / Chesney, Edward; Robson, Deborah; Patel, Rashmi et al.

In: Schizophrenia Research, Vol. 238, 23.09.2021, p. 29-35.

Research output: Contribution to journalArticlepeer-review

Harvard

Chesney, E, Robson, D, Patel, R, Shetty, H, Richardson, S, Chang, C-K, McGuire, P & McNeill, A 2021, 'The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study', Schizophrenia Research, vol. 238, pp. 29-35. https://doi.org/10.1016/j.schres.2021.09.006

APA

Chesney, E., Robson, D., Patel, R., Shetty, H., Richardson, S., Chang, C-K., McGuire, P., & McNeill, A. (2021). The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study. Schizophrenia Research, 238, 29-35. https://doi.org/10.1016/j.schres.2021.09.006

Vancouver

Chesney E, Robson D, Patel R, Shetty H, Richardson S, Chang C-K et al. The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study. Schizophrenia Research. 2021 Sep 23;238:29-35. https://doi.org/10.1016/j.schres.2021.09.006

Author

Chesney, Edward ; Robson, Deborah ; Patel, Rashmi et al. / The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study. In: Schizophrenia Research. 2021 ; Vol. 238. pp. 29-35.

Bibtex Download

@article{1312f35d1b1b4e21a5aa8d51a2337d22,
title = "The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study",
abstract = "Severe mental disorders are associated with a life expectancy that is 10–20 years shorter than the general population's. The prevalence of cigarette smoking in these populations is very high. We examined the effect of smoking on life expectancy and survival in patients with a diagnosis of schizophrenia, schizoaffective disorder or bipolar affective disorder from 2007 to 2018 in South East London, UK. Smoking status was determined using unstructured text data extracted from electronic health records. A total of 21,588 patients were identified of which 16,717, (77.4%) were classified as current smokers and 3438 (15.9%) as non-smokers. In female participants, life expectancy at birth was 67.6 years in current smokers (95% CI: 66.4–68.8) and 74.9 years in non-smokers (95% CI: 72.8–77.0), a difference of 7.3 years. In male participants, life expectancy at birth was 63.5 years in current smokers (95% CI: 62.5–64.5) and 68.5 years in non-smokers (95% CI, 64.4–72.6), a difference of 5.0 years. Adjusted survival models found that current smoking status was associated with an increased mortality risk for both females (aHR: 1.42, 95% CI: 1.21–1.66, p < 0.001) and males (aHR: 1.49; 95% CI: 1.25–1.79, p < 0.001). In terms of the effect sizes, these risks were similar to those associated with a diagnosis of co-morbid alcohol or opioid use disorder. Smoking may account for a substantial proportion of the reduced life expectancy in patients with psychotic disorders. Increased emphasis on reducing cigarette smoking in these populations may be the most effective way to reduce the mortality gap with the general population.",
author = "Edward Chesney and Deborah Robson and Rashmi Patel and Hitesh Shetty and Sol Richardson and Chin-Kuo Chang and Philip McGuire and Ann McNeill",
note = "Funding Information: EC is funded by a National Institute for Health Research Doctoral Research Fellowship ( NIHR300273 ). Funding Information: This research was supported by the Biomedical Research Nucleus data management and informatics facility at South London and Maudsley NHS Foundation Trust, which is funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and a joint infrastructure grant from Guy's and St Thomas' Charity and the Maudsley Charity.EC is funded by a National Institute for Health Research Doctoral Research Fellowship (NIHR300273).RP has received support from a Medical Research Council (MRC) Health Data Research UK Fellowship (MR/S003118/1) and a Starter Grant for Clinical Lecturers (SGL015/1020) supported by the Academy of Medical Sciences, The Wellcome Trust, MRC, British Heart Foundation, Arthritis Research UK, the Royal College of Physicians and Diabetes UK.C-KC was funded by the NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology, and Neuroscience, King's College London. C-KC had received research funding from recent Roche cooperation (negative symptoms and the other dementia studies). No support from any other organisation for the submitted work and no other relationships or activities that could appear to have influenced the submitted work as declared.DR and AM are part funded by the NIHR Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. AM is an NIHR Senior Investigator. The views expressed are those of the authors] and not necessarily those of the NIHR or the Department of Health and Social Care. Funding Information: This research was supported by the Biomedical Research Nucleus data management and informatics facility at South London and Maudsley NHS Foundation Trust, which is funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and a joint infrastructure grant from Guy's and St Thomas' Charity and the Maudsley Charity . Funding Information: RP has received support from a Medical Research Council (MRC) Health Data Research UK Fellowship ( MR/S003118/1 ) and a Starter Grant for Clinical Lecturers ( SGL015/1020 ) supported by the Academy of Medical Sciences , The Wellcome Trust , MRC , British Heart Foundation , Arthritis Research UK , the Royal College of Physicians and Diabetes UK . Funding Information: DR and AM are part funded by the NIHR Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. AM is an NIHR Senior Investigator. The views expressed are those of the authors] and not necessarily those of the NIHR or the Department of Health and Social Care. Funding Information: C-KC was funded by the NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology, and Neuroscience, King's College London . C-KC had received research funding from recent Roche cooperation (negative symptoms and the other dementia studies). No support from any other organisation for the submitted work and no other relationships or activities that could appear to have influenced the submitted work as declared. Publisher Copyright: {\textcopyright} 2018",
year = "2021",
month = sep,
day = "23",
doi = "10.1016/j.schres.2021.09.006",
language = "English",
volume = "238",
pages = "29--35",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study

AU - Chesney, Edward

AU - Robson, Deborah

AU - Patel, Rashmi

AU - Shetty, Hitesh

AU - Richardson, Sol

AU - Chang, Chin-Kuo

AU - McGuire, Philip

AU - McNeill, Ann

N1 - Funding Information: EC is funded by a National Institute for Health Research Doctoral Research Fellowship ( NIHR300273 ). Funding Information: This research was supported by the Biomedical Research Nucleus data management and informatics facility at South London and Maudsley NHS Foundation Trust, which is funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and a joint infrastructure grant from Guy's and St Thomas' Charity and the Maudsley Charity.EC is funded by a National Institute for Health Research Doctoral Research Fellowship (NIHR300273).RP has received support from a Medical Research Council (MRC) Health Data Research UK Fellowship (MR/S003118/1) and a Starter Grant for Clinical Lecturers (SGL015/1020) supported by the Academy of Medical Sciences, The Wellcome Trust, MRC, British Heart Foundation, Arthritis Research UK, the Royal College of Physicians and Diabetes UK.C-KC was funded by the NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology, and Neuroscience, King's College London. C-KC had received research funding from recent Roche cooperation (negative symptoms and the other dementia studies). No support from any other organisation for the submitted work and no other relationships or activities that could appear to have influenced the submitted work as declared.DR and AM are part funded by the NIHR Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. AM is an NIHR Senior Investigator. The views expressed are those of the authors] and not necessarily those of the NIHR or the Department of Health and Social Care. Funding Information: This research was supported by the Biomedical Research Nucleus data management and informatics facility at South London and Maudsley NHS Foundation Trust, which is funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and a joint infrastructure grant from Guy's and St Thomas' Charity and the Maudsley Charity . Funding Information: RP has received support from a Medical Research Council (MRC) Health Data Research UK Fellowship ( MR/S003118/1 ) and a Starter Grant for Clinical Lecturers ( SGL015/1020 ) supported by the Academy of Medical Sciences , The Wellcome Trust , MRC , British Heart Foundation , Arthritis Research UK , the Royal College of Physicians and Diabetes UK . Funding Information: DR and AM are part funded by the NIHR Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. AM is an NIHR Senior Investigator. The views expressed are those of the authors] and not necessarily those of the NIHR or the Department of Health and Social Care. Funding Information: C-KC was funded by the NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology, and Neuroscience, King's College London . C-KC had received research funding from recent Roche cooperation (negative symptoms and the other dementia studies). No support from any other organisation for the submitted work and no other relationships or activities that could appear to have influenced the submitted work as declared. Publisher Copyright: © 2018

PY - 2021/9/23

Y1 - 2021/9/23

N2 - Severe mental disorders are associated with a life expectancy that is 10–20 years shorter than the general population's. The prevalence of cigarette smoking in these populations is very high. We examined the effect of smoking on life expectancy and survival in patients with a diagnosis of schizophrenia, schizoaffective disorder or bipolar affective disorder from 2007 to 2018 in South East London, UK. Smoking status was determined using unstructured text data extracted from electronic health records. A total of 21,588 patients were identified of which 16,717, (77.4%) were classified as current smokers and 3438 (15.9%) as non-smokers. In female participants, life expectancy at birth was 67.6 years in current smokers (95% CI: 66.4–68.8) and 74.9 years in non-smokers (95% CI: 72.8–77.0), a difference of 7.3 years. In male participants, life expectancy at birth was 63.5 years in current smokers (95% CI: 62.5–64.5) and 68.5 years in non-smokers (95% CI, 64.4–72.6), a difference of 5.0 years. Adjusted survival models found that current smoking status was associated with an increased mortality risk for both females (aHR: 1.42, 95% CI: 1.21–1.66, p < 0.001) and males (aHR: 1.49; 95% CI: 1.25–1.79, p < 0.001). In terms of the effect sizes, these risks were similar to those associated with a diagnosis of co-morbid alcohol or opioid use disorder. Smoking may account for a substantial proportion of the reduced life expectancy in patients with psychotic disorders. Increased emphasis on reducing cigarette smoking in these populations may be the most effective way to reduce the mortality gap with the general population.

AB - Severe mental disorders are associated with a life expectancy that is 10–20 years shorter than the general population's. The prevalence of cigarette smoking in these populations is very high. We examined the effect of smoking on life expectancy and survival in patients with a diagnosis of schizophrenia, schizoaffective disorder or bipolar affective disorder from 2007 to 2018 in South East London, UK. Smoking status was determined using unstructured text data extracted from electronic health records. A total of 21,588 patients were identified of which 16,717, (77.4%) were classified as current smokers and 3438 (15.9%) as non-smokers. In female participants, life expectancy at birth was 67.6 years in current smokers (95% CI: 66.4–68.8) and 74.9 years in non-smokers (95% CI: 72.8–77.0), a difference of 7.3 years. In male participants, life expectancy at birth was 63.5 years in current smokers (95% CI: 62.5–64.5) and 68.5 years in non-smokers (95% CI, 64.4–72.6), a difference of 5.0 years. Adjusted survival models found that current smoking status was associated with an increased mortality risk for both females (aHR: 1.42, 95% CI: 1.21–1.66, p < 0.001) and males (aHR: 1.49; 95% CI: 1.25–1.79, p < 0.001). In terms of the effect sizes, these risks were similar to those associated with a diagnosis of co-morbid alcohol or opioid use disorder. Smoking may account for a substantial proportion of the reduced life expectancy in patients with psychotic disorders. Increased emphasis on reducing cigarette smoking in these populations may be the most effective way to reduce the mortality gap with the general population.

UR - http://www.scopus.com/inward/record.url?scp=85115411600&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2021.09.006

DO - 10.1016/j.schres.2021.09.006

M3 - Article

VL - 238

SP - 29

EP - 35

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454